Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature

References

• Löhr JM, Beuers U, Vujasinovic M, UEG guideline working group, et al. European guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United European Gastroenterol J. 2020;8(6):637–666.
   PubMed Web of Science ®Google Scholar
• Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–1776.
   PubMed Web of Science ®Google Scholar
• Soliman H, Vullierme MP, Marie F, et al. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. United European Gastroenterol J. 2019;7(8):1073–1083.
   PubMed Web of Science ®Google Scholar
• Vujasinovic M, Valente R, Maier P, et al. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. Pancreatol. 2018;18(8):900–904.
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Wallace ZS, Crowe JL, Second International Symposium on IgG4-Related Disease, et al. International consensus guidance statement on the management and treatment of IgG4-Related disease. Arthritis Rheumatol. 2015;67(7):1688–1699.
   PubMed Web of Science ®Google Scholar
• Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1438–1439.
   PubMed Web of Science ®Google Scholar
• Yoon SB, Moon SH, Kim JH, et al. Determination of the duration of glucocorticoid therapy in type 1 autoimmune pancreatitis: a systematic review and Meta-analysis. Pancreatology. 2021. DOI:https://doi.org/10.1016/j.pan.2021.05.303.
   Web of Science ®Google Scholar
• Okazaki K, Kawa S, Kamisawa T, Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2010;45(3):249–265.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Okazaki K, Kawa S, Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45(5):471–477.
   PubMed Web of Science ®Google Scholar
• Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo clinic experience. Gut. 2013;62(11):1607–1615.
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: Pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2(9):731–743.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (London, England). 2009;374(9701):1617–1625.
   PubMed Web of Science ®Google Scholar
• Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol. 2014;134(3):679–687.
   PubMed Web of Science ®Google Scholar
• Shimosegawa T, Chari ST, Frulloni L, International Association of Pancreatology, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40(3):352–358.
   PubMed Web of Science ®Google Scholar
• Lopez-Serrano A, Crespo J, Pascual I, Members of the Autoimmune Pancreatitis in Spain Study Group, et al. Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the international consensus Diagnostic Criteria: A multi-centre study. Pancreatology. 2016;16(3):382–390.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and Meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–974.
   PubMed Web of Science ®Google Scholar
• Backhus J, Neumann C, Perkhofer L, et al. A Follow-Up study of a european IgG4-Related disease cohort treated with rituximab. J Clin Med. 2021;10(6):1329.
   PubMed Web of Science ®Google Scholar
• Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a french nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease. Eur J Intern Med. 2020;74:92–98.
   PubMed Web of Science ®Google Scholar
• Barresi L, Tacelli M, Crino SF, Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO), Italian Association for the Study of the Pancreas (AISP), et al. Multicentric italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency. United European Gastroenterol J. 2020;8(6):705–715.
   PubMed Web of Science ®Google Scholar
• Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–1177.
   PubMed Web of Science ®Google Scholar
• Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol. 2018;16(12):1947–1953.
   PubMed Web of Science ®Google Scholar
• Su Y, Sun W, Wang C, et al. Detection of serum IgG4 levels in patients with IgG4-Related disease and other disorders. PLoS One. 2015;10(4):e0124233.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Mattoo H, Mahajan VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford)). 2016;55(6):1000–1008.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Igarashi T, Itoh K, IDEC-C2B8 Study Group, et al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci. 2011;102(9):1698–1705.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Saag K, Cascino MD, et al. Long-Term safety of rituximab in patients with rheumatoid arthritis: Results of a Five-Year observational study. Arthritis Care Res. 2019;71(8):993–1003.
   Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896–3908.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Vinge-Holmquist O, Overbeek KA, et al. PrescrAIP: a Pan-European study on current treatment regimens of Auto-Immune pancreatitis. Front Med (Lausanne)). 2020;7:408.
   PubMed Web of Science ®Google Scholar